clinical trial · NCT03071965
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)
MacTel (Macular Telangiectasia) Type 2Ciliary neurotrophic factor (CNTF)SurgerySurgery
brief summary
This was a prospective, multicenter, single-masked, sham-controlled extension study designed to provide long-term safety and efficacy follow-up data for subjects with MacTel who had NT-501 implanted intraocularly and/or underwent sham surgery in the respective precursor study (NTMT-01 or NTMT-02). A substudy was conducted in which subjects enrolled in study (NTMT-02), who had 1 study-eligible eye that underwent sham surgery, were offered the option to have NT-501 implanted in the same study eye. Of the 19 subjects who had 1 study-eligible eye and underwent sham surgery in the Cohort 2 precursor study (NTMT-02), 16 subjects elected to have NT-501 implanted in the same study eye during the substudy
started
May 12, 2017
primary completion
May 11, 2021
completion
May 11, 2021
last updated
May 9, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol